Drugs.com - New Drug Approvals

FDA Approves Datroway (datopotamab deruxtecan-dlnk) for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

WILMINGTON, Del.-- January 17, 2025 -- Datroway (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+ or IHC...

Feb 9, 2025 - 22:25
 0
FDA Approves Datroway (datopotamab deruxtecan-dlnk) for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
WILMINGTON, Del.-- January 17, 2025 -- Datroway (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+ or IHC...
Read More

Tags:

Previous Article

Spravato (esketamine) Approved in the U.S. as the First and Only Monotherapy for...

Next Article

Calquence Plus Chemoimmunotherapy Approved in the U.S. for Patients with Previou...

Related Posts

U.S. FDA Approves Pfizer’s Braftovi Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer

U.S. FDA Approves Pfizer’s Braftovi Combination Regimen...

Feb 9, 2025  0

FDA Approves Ospomyv (denosumab-dssb), a Biosimilar to Prolia

FDA Approves Ospomyv (denosumab-dssb), a Biosimilar to ...

Feb 17, 2025  0

Rhythm Pharmaceuticals Announces FDA Approval of Imcivree (setmelanotide) for Patients as Young as 2 Years Old

Rhythm Pharmaceuticals Announces FDA Approval of Imcivr...

Feb 9, 2025  0